Journal of Women in Educational Leadership

57 A Breath of Spring Air- Marilyn L. Grady 59 Female Middle School Principals\u27 Voices: Implications for School Leadership Preparation- Cathy Jones, Martha N, Ovando and Cynthia High 77 Women and Tenure: Closing the Gap- Anne M. Schoening 93 Book Review-Female Leadership for Foster Care Youth- John M. Palladino and Mark A. Giesle

Journal of Women in Educational Leadership

The JOURNAL OF WOMEN IN EDUCA TIONAL LEADERSHIP (ISSN 1541-6224) Published quarterly January, April, July and October, one volume per year, by ProActive Publications, 439 North Duke Street, Lan- caster, PA 17602-4967. POSTMASTER: Send address changes to Journal of Women in Educational Leader- ship, 439 North Duke Street, Lancaster, PA 17602-4967

Journal of Women in Educational Leadership

1 Miep Gies (1909-2010): Her Legacy Endures- Marilyn L. Grady 3 Gender Differences in Research Mentorship and Pretenured Counselor Educators- Suzanne Campbell, Kathryn Mueller and Jane M. Souz

A signalome screening approach in the autoinflammatory disease TNF Receptor Associated Periodic Syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing

TNF Receptor Associated Periodic Syndrome (TRAPS) is an autoinflammatory disease caused by mutations in TNF Receptor 1 (TNFR1). Current therapies for TRAPS are limited and do not target the pro-inflammatory signalling pathways that are central to the disease mechanism. Our aim was to identify drugs for repurposing as anti-inflammatories based on their ability to down-regulate molecules associated with inflammatory signalling pathways that are activated in TRAPS. This was achieved using rigorously optimised, high through- put cell culture and reverse phase protein microarray systems to screen compounds for their effects on the TRAPS-associated inflammatory signalome. 1360 approved, publically available, pharmacologically active substances were investigated for their effects on 40 signalling molecules associated with pro-inflammatory signalling pathways that are constitutively upregulated in TRAPS. The drugs were screened at four ten-fold concentrations on cell lines expressing both wild-type (WT) TNFR1 and TRAPS-associated C33Y mutant TNFR1, or WT TNFR1 alone; signalling molecule levels were then determined in cell lysates by the reverse phase protein microarray. A novel mathematical methodology was developed to rank the compounds for their ability to reduce the expression of signalling molecules in the C33Y-TNFR1 transfectants towards the level seen in the WT-TNFR1 transfectants. Seven high-ranking drugs were selected and tested by RPPA for effects on the same 40 signalling molecules in lysates of peripheral blood mononuclear cells (PBMCs) from C33Y-TRAPS patients compared to PBMCs from normal controls. The fluoroquinolone antibiotic lomefloxacin, as well as others from this class of compounds, showed the most significant effects on multiple pro-inflammatory signalling pathways that are constitutively activated in TRAPS; lomefloxacin dose-dependently significantly reduced expression of 7/40 signalling molecules across the Jak/Stat, MAPK, NF-kB and PI3K/AKT pathways. This study demonstrates the power of signalome screening for identifying candidates for drug repurposing

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Journal of Women in Educational Leadership

57 A Breath of Spring Air- Marilyn L. Grady 59 Female Middle School Principals\u27 Voices: Implications for School Leadership Preparation- Cathy Jones, Martha N, Ovando and Cynthia High 77 Women and Tenure: Closing the Gap- Anne M. Schoening 93 Book Review-Female Leadership for Foster Care Youth- John M. Palladino and Mark A. Giesle

Journal of Women in Educational Leadership Vol. 7 No. 3

105 The Midwest Women\u27s Leadership Institute: Pointing the Way- Marilyn L. Grady 107 Ethical Leadership: What Does It Look Like?- Laura Schulte 115 Perceptions of Leadership Behaviors by Female Principals in North Carolina -Cheryl McFadden, Cathy Maahs-Fladung, Susan Beck-Frazier and Kermit Bruckner 135 Women Superintendents In Illinois: Gender Barriers and Challenges- Vicki VanTuyle and Sandra G, Watkin

Journal of Women in Educational Leadership

The JOURNAL OF WOMEN IN EDUCA TIONAL LEADERSHIP (ISSN 1541-6224) Published quarterly January, April, July and October, one volume per year, by ProActive Publications, 439 North Duke Street, Lan- caster, PA 17602-4967. POSTMASTER: Send address changes to Journal of Women in Educational Leader- ship, 439 North Duke Street, Lancaster, PA 17602-4967

CRIDA News Letter July- December 2014

Not AvailableNot AvailableNot Availabl